




**Ciências
ULisboa**



**REPÚBLICA
PORTUGUESA**
SAÚDE

Instituto Nacional de Saúde
Doutor Ricardo Jorge





Oncobiology

Margarida Gama-Carvalho (DQB/FCUL) and Peter Jordan (INSA)




Cell Signalling – part 2

repetition: The RAS-MAP kinase pathway






Plasma membrane lipids




Phosphatidyl-


Phosphatidyl-




PA
acid




PI
inositol



PS
serine




PE
ethanolamine




PC
choline

Plasma membrane lipids show an asymmetric distribution



Why asymmetric?

- PI generates second messengers (PLC: IP3 + DAG; PI3K: PIP3)
- PS at outer leaflet marks apoptotic cells





Phosphatidyl-inositol-derived second messengers




group 1: IP3 and DAG

e. g: T Cell
Receptor (TCR)
Signaling


via Phospholipase C



Phosphatidyl-inositol-derived second messenger: group 2: phosphorylation at position 3




Glucose




Inositol

The PI3 kinase pathway

$PI_{(3,4,5)}P_3$
=
anchor for
recruitment of
cytoplasmic PH-
domain containing
protein kinases to the
membrane for their
activation



PI3-kinase activation




p110 α ,
PIK3CA gene

- Class IA PI3K molecules are **heterodimers** composed of
1. a regulatory, SH2 domain-containing subunit (p85) and
 2. a catalytic (p110) subunit (*PIK3CA* gene).

The PI3 kinase pathway


$PI_{(3,4,5)}P_3$ = anchor for recruitment of PH-domain proteins



1- Ligand-receptor complex leads to PI3K activation via SH2 domains


2- Recruitment of cytoplasmic protein kinases to the membrane for their activation

PI3K-AKT pathway



The PI3 kinase pathway

$PI_{(3,4,5)}P_3$ = anchor for recruitment of PH-domain proteins



Genetic alterations that activate the pathway in tumours

PTEN


Gene deletion or
gene silencing



Brain and breast
tumours

PTEN tumour suppressor gene

Lipid phosphatase required
to terminate the signal



PIK3CA oncogene

Gain-of-function missense mutations
lead to receptor-independent activation

PI3K-AKT pathway

Oncogenic PIK3CA mutations






Fig. 1. Mutations in *PIK3CA*. Arrowheads indicate the location of missense mutations
 Samuels et al., (2004) Science. 2004 304,554. (updated)

2 modes of PI3K activation




What is AKT doing?




PI3K-AKT pathway

PI3K-AKT signalling: 1) Anti-apoptotic signalling



PI3K-AKT signalling:
2) Cell growth stimulation via mTOR

Rapamycin-
 Antifungal compound isolated from *Streptomyces hygroscopicus* in 1972;
 (FDA approved in 1999 as Sirolimus)




mTOR=
 Mammalian target of rapamycin,
 a protein kinase
 (FKBP12-rapamycin-associated protein (FRAP))

Cell growth
Protein synthesis
Metabolism

PI3K-AKT signalling: 2) Cell growth stimulation via mTOR


4 min-video recommendation:
<https://www.youtube.com/watch?v=ewgLd9N3s-4>



PI3K-AKT signalling: 2) Cell growth stimulation via mTOR


4 min-video recommendation:
<https://www.youtube.com/watch?v=ewgLd9N3s-4>

mTOR as a signalling hub that integrates growth signals and nutritional conditions with cell growth



Genetic changes found in the PI3K-AKT pathway

- Mutation



- PIK3CA

CRC

20%

Esoph

6%

Panc

2%

Gastric

22%

HCC

<1%

- PIK3R1

4%

4%

2%

4%

1%

- AKT

3%

<1%

4%

4%

<1%

- PTEN

4%

3%

2%

6%

<1%

- MTOR

7%

2%

2%

8%

3%

- Amplification

- PIK3CA

19%

?

4%

6%

<1%

- Epigenetic


- PTEN loss

15%

14%

12%

RTKs (HER2, MET, FGFR ecc)



PI3K pathway inhibitors

AKT inhibitors - 27%
mTOR inhibitors - 10%

PI3K Inhibitor

Over 50 compounds in development or clinical use

37% **Specific PI3K Inhibitors**

20% **Dual PI3K/mTOR Inhibitors**
Dactolisib

bind to ATP-binding site of PI3K and mTOR kinase

Pan-PI3K Isoforms Inhibitor 27%
Pictilisib

Isoforms Specific Inhibitors 10%

4%
Alpelisib


Selective PI3K α Inhibitor

Selective PI3K β Inhibitor


Selective PI3K γ Inhibitor

Selective PI3K δ Inhibitor

Take 5 minutes: a PI3K-AKT pathway poster




Graphical abstract of
key tumour-promoting
cancer cell signalling pathways



Activation and inactivation of signalling proteins by reversible post-translational modifications


- | | |
|---------------------|-----------------|
| - Phosphorylation | - Ser, Thr, Tyr |
| - O-GalNAcetylation | - Ser, Thr |
| - N-GlcNAcetylation | - Asn |
| - Sulfation | - Tyr |
| - Ubiquitylation | - Lys |
| - Acetylation | - Lys |
| - Methylation | - Lys, Arg |
| - Oxidation | - Cys |
| - Nitrosylation | - Cys |
| - (...) | |

ubiquitylation




Different types of ubiquitylation

b



Monoubiquitination


Signaling
Endocytosis
DNA repair



Multiple monoubiquitination

Signaling
Endocytosis

**e.g. of
receptors**




Homotypic polyubiquitination - 8 different linkages

Lys6
DNA repair

Lys11
ERAD
Cell cycle

Lys27
Ubiquitin fusion degradation

Lys29
Lysosomal degradation
Kinase modification



Lys33
Kinase modification

Lys48
Proteasomal degradation

Lys63
Signaling
Trafficking
DNA damage response
Innate and adaptive immunity

Met1 (linear)
Signaling


Protein ubiquitylation can serve to


- mark proteins for degradation by the proteasome
- recruit other signalling proteins

 Husnjak K, Dikic I. 2012.
Annu. Rev. Biochem. 81:291–322

→ More than 5 000 ubiquitylated proteins exist in the human proteome (~**25%**) (Kim et al. 2011 MolCell 44)

Ubiquitin-mediated signalling, example 1: Role of Lys48-ubiquitylation for proteolysis during the activation of transcription factor NF- κ B





E1 Ub activating enzyme (2)
E2 Ub conjugating enzyme (37)
E3 Ub ligase (~800)

writer

Ub
UBD

~350

reader

Ubiquitin
Deubiquitinases (~85)

eraser

writer

P
PBD

reader

Kinases (518)


Phosphatases (~120)

eraser


Ubiquitin-mediated signalling, example 2: Role of Lys63-ubiquitylation for NF-κB

UBD- Ubiquitin-binding domain
=
Reader:
Protein domain for recognition
to Ub-chain-modified proteins

Protein ubiquitylation
can serve as a **platform**
for **protein interaction**
that promotes protein
kinase activation




Regulation of signalling proteins by ubiquitin-mediated proteolysis




Irreversible
(except through *de novo* synthesis)

Proteolysis controls the unidirectional progression of the cell cycle

Cyclins are required for the activity of cyclin-dependent protein kinases




WNT pathway controls the transcriptional cofactor β -catenin



Default phosphorylation and proteolytic degradation


Receptor
↓
Protein kinase inhibition
↓
Transcription factor stabilization

Membrane proteases in Notch signalling




Activation and inactivation of signalling proteins by reversible post-translational modifications

- | | |
|---------------------|-----------------|
| - Phosphorylation | - Ser, Thr, Tyr |
| - O-GalNAcetylation | - Ser, Thr |
| - N-GlcNAcetylation | - Asn |
| - Sulfation | - Tyr |
| - Ubiquitylation | - Lys |
| - Acetylation | - Lys |
| - Methylation | - Lys, Arg |
| - Oxidation | - Cys |
| - Nitrosylation | - Cys |
| - (...) | |



1. decreases the electrostatic interaction of histones with DNA, allowing transcription
2. Recognition by bromodomain-containing proteins (46 BRD protein genes)

Epigenetic regulation of gene expression




Activation and inactivation of signalling proteins by reversible post-translational modifications

- | | |
|---------------------|-----------------|
| - Phosphorylation | - Ser, Thr, Tyr |
| - O-GalNAcetylation | - Ser, Thr |
| - N-GlcNAcetylation | - Asn |
| - Sulfation | - Tyr |
| - Ubiquitylation | - Lys |
| - Acetylation | - Lys |
| - Methylation | - Lys, Arg |
| - Oxidation | - Cys |
| - Nitrosylation | - Cys |
| - (...) | |

Cancer cell glycome - Changes in glycosylation of **cell surface adhesion molecules** (selectin ligands, integrins and mucins) are associated with the progression of cancers and can have prognostic implications.

<https://doi.org/10.1038/nrc3982> - Salomé Pinho & Celso Reis

- interfere with epithelial cadherin-mediated cell-cell adhesion;
- modulate tumour cell-matrix interactions;
- hide tumour-cell surface antigens from immune cells;
- regulate immune cell activation.



Lecture 5- Some take-home concepts

- Besides the RAS-MAPK pathway, the PI3K/AKT pathway is another tumour-promoting pathway;
- Growth factor receptor-mediated activation of PI3K leads to phosphorylation of the plasma membrane lipid PI, which then is recognized by PH domain-containing proteins, including AKT;
- Activated AKT phosphorylates target proteins leading both, to activation of mTOR and cell growth promotion, and to inhibition of apoptosis;
- Oncogenic alterations leading to pathway activation include loss of PTEN and missense mutations in PIK3CA.
- Regulation of protein activation during cell signalling also occurs through other post-translational protein modifications, including ubiquitylation, acetylation, cysteine oxidation, or glycosylation